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Abstract: Members of the Ether-à-go-go (Eag) group of potassium channels, including the human Ether-à-go-go (hEag) 
and the human Ether-à-go-go-related gene (hERG) ion channels, have been shown to play important roles in cancer 
pathogenesis and to regulate many aspects of tumour development. It was shown that they are frequently overexpressed 
or ectopically expressed in different human cancers, which, combined with their cell surface expression, led to different 
attempts at finding their therapeutic potential as promising cancer therapy targets. This review summarizes the current 
knowledge drawn from the results of independent studies performed to identify sought-after alternatives of targeting these 
ion channels in cancer therapy. 
INTRODUCTION 
Ion channels are transmembrane proteins that allow the passive passage of specific ions through the plasma membrane. 
Their cell surface expression is correlated with a high therapeutic potential, since many drugs targeting them may not 
need to enter into cells to exert their beneficial effects. Such therapeutic effects usually consist either in blocking the ion 
conduction or oppositely, to activate the channel’s function and sustain an overly increased flow through them. Although 
ion channels form a large pharmacological target group, no ion channel is currently targeted in antitumour therapy, 
despite recent intense efforts directed towards deciphering their role, expression and therapeutic potential, which lead to 
an impressive accumulation of experimental data (Becchetti et al, 2013). 
There are many identified ion channels which play roles in the progression of cancer, but evidence accumulates in favor 
of potassium (K+) channels, which are frequently overexpressed in tumour cells and have been demonstrated to play roles 
in basically all cancer cell-specific physiological processes (Huang and Jan, 2014). A particular group in the K+ channels 
superfamily is named Ether-à-go-go, or Eag. In humans, this group is formed by the Ether-à-go-go (hEag), Ether-à-go-go-
related gene (hERG) and Ether-à-go-go-like (hELK) ion channels. They all share several structural features, but have 
different physiological parameters. Each one of the channels may be coded by different genes (for example, hEag1 is 
coded by KCNH1 while hEag2 is coded by KCNH5) and may present different isoforms after differential splicing. All 
channels have various, but different, functions in the human body. The hEag channel is expressed in fusing myoblasts, the 
retina and the central nervous system. The hERG channels are expressed in a wide variety of tissues, being critically 
responsible for conducting the rapid depolarizing current which follows the cardiac action potential, which is why several 
non-specific hERG1 blockers have been withdrawn from the market, as the channel became an important pharmaceutical 
antitarget (Raschi et al, 2008). 
The Eag channels have important roles in cancer cells of various origins (Tang et al, 2016). They have been shown to 
possess oncogenic properties when their expression is enlarged and are also frequently expressed or overexpressed in 
tumour cells (Camacho, 2006; Hemmerlein et al, 2006). A large amount of evidence emerged, all of which show how 
hEag and hERG channels interact and regulate specific cancer cells functions. In fact, hEag has a limited tissue 
distribution, but combined with its ectopic expression in cancer makes it a highly suitable biomarker and potential 
antitumour target, unlike hERG, which is expressed more ubiquitously and its blockade has serious cardiac side effects. 
The channels play important roles in cancer cells and regulate several aspects of cancer pathogenesis and progression 
(Arcangeli and Becchetti, 2015). Here, we present several lines of evidence that emerged during recent years regarding 
the potential of Eag channels as promising anticancer targets and the various strategies that were demonstrated to have 
limited experimental benefits. Then, we present several perspectives, which could well be considered to be further 
employed in order to draw new information about these channels and to ultimately target them in cancer therapy. 
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TARGETING EAG CHANNELS WITH SMALL MOLECULES 
Targeting ion channels by small molecules is currently used in treating a variety of conditions, 
due to the accessible location of ion channels (Bagal et al, 2013). An impressive number of 
compounds have been found to inhibit the hERG ion channel, due to its unique large cavity 
which can accommodate many types of blockers. Interestingly, most known blockers of hERG 
and hEag, like imipramine or astemizole, have been shown to inhibit cell proliferation in some 
cancer cell lines by targeting hERG (García-Ferreiro et al, 2004). However, most hERG blockers 
are also blockers of hEag, therefore it was assumed that the anticancer effects could be due to 
blocking both K+ currents at once. Nevertheless, hERG blockers usually have a lower affinity for 
the hEAG channels, which is usually attributed to the lack of inactivation of the latter. 
Inactivation of hERG is thought to favor a much better placement of important residues in the 
lower cavity, to contact the blocking compounds (Perry et al, 2010), even though there are some 
identified exceptions to this general rule, (see below). In fact, to date, it was difficult to make any 
correct interpretation of the role of hEag1, since there is no specific potent hEag1 blocker. Such a 
blocker would have important consequences, as it should have important antitumour properties, 
given the fact that specific hEag1 antibodies have been shown to significantly decrease 
proliferation of cancer cells (explained in another part of the manuscript). An interesting 
challenge could be finding through drug design processes or high-throughput screening certain 
compounds which could bind differently to the ion channels’ inner cavity, thus having an 
increased blocking effect on hEag1 and not on the related hERG channels. Such a hypothesis was 
recently launched as it is believed that clofilium, another non-specific blocker, could be 
chemically modified to specifically target hEag1, given its particular blocking determinants 
(Șterbuleac and Maniu, 2016). Particular structural features of the two channels (on the 
intracellular activation gate), combined with a new binding mode of clofilium to the hERG 
channel, would mean that increasing the polarity of the molecule near the phenyl group should 
generate the needed larger affinity for the hEAG1 channel (Șterbuleac and Maniu, 2018). Since 
hERG blockers exert different types of side effects, not all of which are very dangerous, it was 
also hypothesized that they could be repurposed for cancer therapy under careful monitoring 
(Huang and Jan, 2014). 
Another promising potential was brought up, regarding the involvement of hERG channels in 
leukemias. The hERG-encoding gene, KCNH2, expresses at least two different hERG isoforms, 
A and B, corresponding to two different ion channels, hERG1A and hERG1B (Gasparoli et al, 
2015). It was noticed that hERG1A is the dominant form expressed in myocytes, but hERG1B is 
frequently overexpressed in leukemias. A promising drug candidate has been identified, which is 
able to block the hERG1B ion channel without interfering with hERG1A function, named CD-
160130. It was also shown that this drug has important in vitro and in vivo antileukemic effects, 
thus opening the door to subsequent research in this promising alternative anticancer combination 
between target and targeting compound. 
TARGETING EAG CHANNELS WITH ANTIBODIES 
Employing antibody therapy in cancer therapeutics is being given full consideration, due to 
recent advances in this research field (Wold et al, 2016)⁠, but significant progress is still awaiting 
in order to use this approach to block ion channels function and treat human diseases (Sun and 
Li, 2013). In order to identify novel therapeutic ion channels antibodies, several issues have to be 
addressed (Wilkinson et al, 2015). In fact, the first monoclonal antibody that specifically 
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inhibited only one K+ channel from this group, hEag1, showed that specific targeting of this 
channel has important antitumour activity (Gómez-Varela et al, 2007). This antibody had 
antigrowth effect in vivo and on several cell lines expressing hEag1. As such, it showed that sole 
blockade of hEag1 is sufficient for good anticancer effects. However, as far as we know, no other 
similar studies were designed. 
TARGETING GENE EXPRESSION BY siRNA 
Small-interfering RNA (siRNA) therapy is a promising new field of research and relies on using 
specific RNA molecules which should combine with cellular RNA transcripts and silence the 
respective gene (Gavrilov and Saltzman, 2012). Nevertheless, it faces serious challenges, 
probably the most important one relying on the challenges to design carriers to deliver siRNA to 
target specific cells. This method consists in applying small RNA molecules complementary to 
the mRNA, therefore silencing specific gene expressions. In line with other studies previously 
presented, silencing the Eag channels’ gene expression also revealed antitumour properties, but 
these studies were performed only using cancer cell cultures. For example, hEag1 siRNA 
significantly reduced proliferation and colony formation (Wu et al, 2015; Weber et al, 2006). 
Little to no effect was observed on apoptosis, suggesting that the effect is cell cycle-specific, but 
significant beneficial effects were observed on cell adhesion and migration of osteosarcoma cell 
lines. A similar study was performed on hERG (Zeng et al, 2016) and showed comparable 
results, although in this case siRNA induced apoptosis. These studies are important since they 
brought additional information regarding the complex cellular signaling processes in which Eag 
channels are involved and include STAT3, VEGF or NF-κB, proteins known to be involved in 
cancer progression. Interestingly, different cellular signaling pathways were activated by 
interfering with each one of the channels. 
DUAL-TARGETING OF EAG CHANNELS 
As presented so far, it can be noticed that the studies performed on the anticancer therapeutic 
potential of these channels either need further extension or show potential limitations. However, 
several lines of evidence exist, showing that using multiple types of channel targeting has 
combined effects. It was demonstrated that a hEag1 specific antibody coupled to the soluble 
tumour necrosis factor-related apoptosis-inducing ligand (sTRAIL), which is a known promising 
anticancer candidate, led to an improved cancer cell-targeting on different cancer cell lines than 
application of antibody alone (Hartung et al, 2011). Using calcitriol (which blocks hEag1 while 
having other beneficial effects) and astemizole combined showed improved in vivo effects than 
application of either one alone, which also attests that more efficient results can be seen by using 
a combined targeting strategy (García-Quiroz et al, 2014). 
PERSPECTIVES 
As mentioned, there are several lines of research that merit full consideration towards finding 
novel anticancer therapeutics or to repurpose other drugs. Clofilium is an interesting candidate to 
be chemically altered and to identify the first hEag specific blockers. Recent structures of hERG1 
and hEag1 were identified and could be used to aid the drug design processes. Then, it would be 
interesting to see if such blockers could be optimized for lesser toxicity and would have 
anticancer effects. Indeed, an alternative approach is a comprehensive screening of a large 
compound library, in order to identify specific potent hEag1 blockers or chemical features of 
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such a blocker. Such a study is much sought-after and would bring important information and 
knowledge in this field. 
Other pieces of information are still missing. An integration of the two channels in the complex 
signaling pathways of normal and cancer cells would be quite challenging, but it should rely on a 
comprehensive biochemical and cellular experimental perspective. It should also be based on 
deciphering the precise biogenesis and trafficking of the two channels, which could then be 
integrated altogether in the complex so-far-known architecture of the cellular machinery. Such 
machinery is highly unregulated during cancer, which also leads to a genomic instability, which 
then influences, through mutations, the structure and function of ion channels. It has to be 
analyzed whether disfunction of ion channels occurs as a consequence of genome instability and 
if this can be reversed. 
Antibody therapeutics is another promising line that could bring new evidence about the role of 
Eag channels in cancer cells. Yet, targeting ion channels in cancer with antibodies faces serious 
challenges and the difficulties regarding it might also indicate the scarcity of studies in this 
specific field. Nevertheless, given the highly relevance of the Eag channels in cancer 
pathogenesis and the recent evidence, studies should rely on deciphering whether multiple ion 
channels targeting, used in conjunction with other types of anticancer targeting, would bring 
improvements. Interesting results were obtained by combining multiple types of targeting, even if 
such studies were limited to cancer cell cultures. This merits further studies to be also used in a 
clinical basis, thus avoiding hERG-related side effects while personalizing the treatment 
independently for each patient. Targeting Eag could well serve as a means of improving the 
overall classical chemotherapeutic treatment, by integrating Eag blockers in the treatment scheme 
while taking account of patient’s genetic profile or compound metabolism. This is why the 
involvement of Eag channels should also be highlighted using pharmacogenetics approaches, 
which will definitely yield important cellular interactions specific to these channels and that may 
be further employed in other studies. 
CONCLUSIONS 
The Eag channels have important roles in cells and their function is linked to various 
physiological processes. Despite their relatedness, the hERG and hEag play significantly 
different roles in various cell types. It is acknowledged that Eag channels play significant roles in 
cancer progression and their targeting in anticancer therapy is one of the most promising research 
premises in this research area. Several studies showed that interfering with the channels’ function 
leads to anticancer effects. All of the presented strategies merit further development in order to 
relate Eag channels to specific roles played in cancer and to identify clinically-relevant active 
molecules to target Eag channels in cancer therapy. 
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